Fundraising Fox

Adam Simpson

Investor

Venture Partner at Frazier Life Sciences

San Diego

About

Adam Simpson joined Frazier Life Sciences as a Venture Partner in 2024, focusing on company creation. He co-founded and served as CEO of Icosavax (Nasdaq: ICVX), leading it through IPO and acquisition by AstraZeneca, and previously was CEO of PvP Biologics (acquired by Takeda) and co-founder/Chief Business Officer of Meritage Pharma (sold to Shire). He began his career as a life sciences transactions attorney at Latham & Watkins and holds a B.S. in biochemistry from UC San Diego and a J.D. from the University of Minnesota Law School.

Invests in

Biotech

Experience

  1. Frazier Life SciencesVenture Partnercurrent2024 β€” present
  2. Callio TherapeuticsExecutive Board Chaircurrent2024 β€” present
  3. Icosavax, Inc.Chief Executive Officer, Board Member & Co-Founder2017 β€” 2024
  4. PvP Biologics, Inc.Chief Executive Officer & Board Member2016 β€” 2020
  5. Cypher GenomicsPresident & Chief Operating Officer2013 β€” 2016
  6. Meritage Pharma, Inc.Chief Business Officer & Co-Founder2008 β€” 2012
  7. Verus PharmaceuticalsGeneral Counsel2005 β€” 2008
  8. Latham & WatkinsAssociate1999 β€” 2005

Education

  1. UC San DiegoB.S., Biochemistry1992 β€” 1996
  2. University of Minnesota Law SchoolJ.D.1996 β€” 1999

Skills & more

StrategyVenture Capital1CommercializationBiotechnologyGenomicsMergers & AcquisitionsStart-upsLicensingFDAPharmaceutical IndustryVaccines

From Adam's professional profile.

Same school

Shared employers

Investments

Board seats

Callio Therapeutics

Per the firm's website.

Colleagues at Frazier Life Sciences